Abstract
Epidemiological and laboratory findings have long implicated a potential anti-cancer activity of the trace element nutrient selenium (Se). Note that it is often for convenience reasons to describe such anti-cancer activity in terms of the element. A vast volume of data have been accumulated supporting the theme that cancer preventive activity is expressed as a function of the dose and chemical form in which the element resides, not elemental Se per se (1,2). The landmark cancer prevention trial by Clark, Combs and coworkers demonstrated for the first time that a supra-nutritional Se supplement (provided as selenized yeast) to a US skin cancer patient population otherwise adequate in Se nutrition might be an effective preventive agent for several major human epithelial cancers (3). With profound public health implications at stake, many serious issues demand a clear understanding of the mechanisms through which Se exerts anti-cancer activity. Some of these pressing questions, for example, include what form(s) and what doses of Se should be used? What populations should be given the intervention? How long should the intervention be given?
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr. 1998; 128:1845–1854.
Combs GF Jr and Gray WP. Chemopreventive agents: selenium. Pharmacol Ther. 1998; 79:179–192.
Clark LC, Combs GF Jr, Turnbull BW, et. al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996; 276: 1957–1963.
Jiang C, Jiang W, Ip C, Ganther H and Lu JX. Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol. Carcinogenesis. 1999. In press.
Ganther HE. Selenium metabolism, selenoproteins, and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis, 1999. 20:1657–1666. Review.
Ip C and Ganther HE. Activity of methylated forms of selenium in cancer prevention. Cancer Res 1990; 50:1206–1211.
Ip C, Hayes C, Budnick RM, and Ganther FIE. Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 1991; 51:595–600.
Ganther HE. Pathways of selenium metabolism including respiratory excretory products. J Am. Coll. Toxicol. 1986; 5:1–5.
EI-Bayoumy K, Upadhyaya P, Chae YH, Sohn OS, Rao CV, Fiala E, Reddy BS. Chemoprevention of cancer by organoselenium compounds. J Cell Biochem Suppl. 1995; 22:92–100. Review.
Snyder RD. Effects of sodium selenite on DNA and carcinogen-induced DNA repair in human diploid fibroblasts. Cancer Lett. 1987; 34:73–81.
Garberg P, Stahl A, Warholm M, Hogberg J. Studies of the role of DNA fragmentation in selenium toxicity. Biochem Pharmacol. 1988; 37:3401–3406.
Wilson AC, Thompson HJ, Schedin PJ, Gibson NW, Ganther HE. Effect of methylated forms of selenium on cell viability and the induction of DNA strand breakage. Biochem Pharmacol. 1992; 43:1137–41.
Seko Y, Saito Y, Kitahara J. and Imura N. Active oxygen generation by the reaction of selenite with reduced glutathione in vitro. In: Proceedings of the 4thInternational Symposium on Selenium in Biology and Medicine (Ed. Wendel A). Springer, Heidelburg, Germany. 1989. pp 70–73.
Yan L and Spallholz JE. Generation of reactive oxygen species from the reaction of selenium compounds with thiols and mammary tumor cells. Biochem Pharmacol. 1993; 45:429–37.
Lu J, Kaeck M, Jiang C, Wilson AC, Thompson HJ. Selenite induction of DNA strand breaks and apoptosis in mouse leukemic L1210 cells. Biochem Pharmacol. 1994; 47:1531–1535.
LuJ Kaeck MR, Jiang C, Garcia G, Thompson HJ. A filter elution assay for the simultaneous detection of DNA double and single strand breaks. Anal Biochem. 1996; 235:227–233.
Cho DY, Jung U, Chung AS. Induction of apoptosis by selenite and selenodiglutathione in HL-60 cells: correlation with cytotoxicity. Biochem Mol Biol Int. 1999; 47:781–793.
Shen HM, Yang CF, Ong CN. Sodium selenite-induced oxidative stress and apoptosis in human hepatoma HepG2 cells. Int J Cancer. 1999; 81:820–828.
Stewart MS, Spallholz JE, Neldner KH, Pence BC. Selenium compounds have disparate abilities to impose oxidative stress and induce apoptosis. Free Radic Biol Med. 1999; 26:42–48.
Davis RL, Spallholz JE, Pence BC. Inhibition of selenite-induced cytotoxicity and apoptosis in human colonic carcinoma (HT-29) cells by copper. Nutr Cancer. 1998; 32:181–189.
Stewart MS, Davis RL, Walsh LP, Pence BC. Induction of differentiation and apoptosis by sodium selenite in human colonic carcinoma cells (HT29). Cancer Lett. 1997; 117:35–40.
Zhu Z, Kimura M, Itokawa Y, Aoki T, Takahashi JA, Nakatsu S, Oda Y, Kikuchi H. Apoptosis induced by selenium in human glioma cell lines. Biol Trace Elern Res. 1996; 54:123–134.
Lu J, Jiang C, Kaeck M, Ganther H, Vadhanavikit S, Ip C and Thompson HJ. Dissociation of the genotoxic and growth inhibitory effects of selenium. Biochem Pharmacol 1995; 50: 213–219.
Lu J, Pei H, Ip C, Lisk D, Ganther H and Thompson HJ. Effect of an aqueous extract of selenium enriched garlic on in vitro markers and in vivo efficacy in cancer prevention. Carcinogenesis, 1996; 17:1903–1907.
Kaeck M, Lu J, Strange R, Ip C, Ganther HE, Thompson HJ. Differential induction of growth arrest inducible genes by selenium compounds. Biochem Pharmacol 1997; 53:921–926.
Sinha R, Medina D. Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial tumor cells. Carcinogenesis. 1997; 18:1541–1547.
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285:1182–1186.
Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer. 1996; 32A:2534–2539.
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86:353–364.
Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998; 58:1048–1051.
Hiraoka N, Allen E, ApelIJ Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 1998; 95:365–377.
Deryugina EI, Bourdon MA, Reisfeld RA, Strongin A. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metatloproteinase-2. Cancer Res. 1998; 58:3743–3750.
Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med. 1998; 49:407–424.
Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science. 1988; 240:177–184.
Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998; 58:1408–1416.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lu, J. (2001). Apoptosis and Angiogenesis in Cancer Prevention by Selenium. In: Nutrition and Cancer Prevention. Advances in Experimental Medicine and Biology, vol 492. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1283-7_11
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1283-7_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5477-2
Online ISBN: 978-1-4615-1283-7
eBook Packages: Springer Book Archive